[HTML][HTML] Complex implementation factors demonstrated when evaluating cost-effectiveness and monitoring racial disparities associated with [18F]DCFPyL PET/CT in …
K Subramanian, J Martinez… - Scientific Reports, 2023 - nature.com
Prostate cancer (PC) staging with conventional imaging often includes multiparametric
magnetic resonance (MR) of the prostate, computed tomography (CT) of the chest …
magnetic resonance (MR) of the prostate, computed tomography (CT) of the chest …
A prospective phase II/III multicenter study of PSMA-targeted 18F-DCFPyL PET/CT imaging in patients with prostate cancer (OSPREY): A sub-analysis of regional and …
9 Background: Current imaging modalities are suboptimal for the initial staging of men at risk
of harboring occult metastatic prostate cancer (PCa). PSMA-based imaging is considered …
of harboring occult metastatic prostate cancer (PCa). PSMA-based imaging is considered …
18F-DCFPyL PET/CT for primary staging in 160 high-risk prostate cancer patients; metastasis detection rate, influence on clinical management and preliminary …
M Wondergem, FM Van Der Zant, WAM Broos… - European Journal of …, 2021 - Springer
Purpose Prostate-specific membrane antigen (PSMA) PET/CT shows better diagnostic
performance for detection of lymph node and bone metastases as compared to conventional …
performance for detection of lymph node and bone metastases as compared to conventional …
aPROMISE: a novel automated PROMISE platform to standardize evaluation of tumor burden in 18F-DCFPyL images of veterans with prostate cancer
Standardized staging and quantitative reporting are necessary to demonstrate the
association of 18F-DCFPyL PET/CT imaging with clinical outcome. This work introduces an …
association of 18F-DCFPyL PET/CT imaging with clinical outcome. This work introduces an …
Results from the OSPREY trial: A prOspective phase 2/3 multi-center study of 18F-DCFPyL PET/CT imaging in patients with pRostate cancer-examination of diagnostic …
586 Objectives: Prostate-specific membrane antigen (PSMA) is a transmembrane protein
that is overexpressed by prostate cancer (PCa) cells. PSMA-based imaging is considered …
that is overexpressed by prostate cancer (PCa) cells. PSMA-based imaging is considered …
[HTML][HTML] [18F] DCFPyL PET/CT for imaging of prostate cancer
Prostate-specific membrane antigen (PSMA)-directed positron emission tomography (PET)
has gained increasing interest for imaging of men affected by prostate cancer (PC). In recent …
has gained increasing interest for imaging of men affected by prostate cancer (PC). In recent …
Prospective evaluation of 18F-FACBC PET/CT and PET/MRI versus multiparametric MRI in intermediate- to high-risk prostate cancer patients (FLUCIPRO trial)
Purpose The purpose of this study was to evaluate 18 F-FACBC PET/CT, PET/MRI, and
multiparametric MRI (mpMRI) in detection of primary prostate cancer (PCa). Methods Twenty …
multiparametric MRI (mpMRI) in detection of primary prostate cancer (PCa). Methods Twenty …
A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with 18F-DCFPyL in Prostate Cancer Patients …
Purpose: Prostate specific membrane antigen-targeted positron emission tomography/
computerized tomography has the potential to improve the detection and localization of …
computerized tomography has the potential to improve the detection and localization of …
Disparities in PET imaging for prostate cancer at a tertiary academic medical center
MD Bucknor, DY Lichtensztajn, TK Lin… - Journal of Nuclear …, 2021 - Soc Nuclear Med
The purpose of this study was to evaluate differences between patients receiving 18F-
fluciclovine and 68Ga-prostate-specific membrane antigen (68Ga-PSMA-11) for …
fluciclovine and 68Ga-prostate-specific membrane antigen (68Ga-PSMA-11) for …
Detection of clinically significant prostate cancer with 18F-DCFPyL PET/multiparametric MR
U Metser, C Ortega, N Perlis, E Lechtman… - European Journal of …, 2021 - Springer
Purpose To assess whether 18 F-DCFPyL PET/multiparametric (mp) MR contributes to the
diagnosis of clinically significant (cs) prostate cancer (PCa) compared to mpMR in patients …
diagnosis of clinically significant (cs) prostate cancer (PCa) compared to mpMR in patients …